Paper Details

  1. Home
  2. Paper Details

HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.

Author: , Bani-SadrF, DabisF, GilbertC, LokoM A, MorlatP, NeauD, RosenthalE, SalmonD, SimonA, ValantinM A, WittkopL

Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

Boceprevir (BOC) and telaprevir (TVR), first-generation HCV protease inhibitors, achieve 60-70% sustained virological response (SVR) in genotype 1 HCV infected patients. Despite the availability of newer direct-acting antiviral (DAA) drugs like sofosbuvir, BOC and TVR might still be a therapeutic option in resource-limited countries where access to newer DAAs is limited.
Paper Details　
Original Abstract of the Article :
As first generation HCV-specific protease inhibitors, boceprevir (BOC) or telaprevir (TVR) can achieve 60% to 70% sustained virological response (SVR) for HCV infected patients with genotype 1 infections, they could remain temporary a therapeutic option in patients living in resources limited countr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jcv.2015.10.010

データ提供：米国国立医学図書館（NLM）

HCV Viral Load: A Key Predictor of Treatment Success in HIV/Hepatitis C Co-infected Patients

This study explores the world of hepatitis C virus (HCV) infection, a complex and challenging condition that can lead to liver damage. Imagine HCV as a persistent desert wind that erodes the liver, leaving behind scars and potential complications. This study investigates the role of HCV viral load, a measure of the amount of virus in the blood, as a predictor of treatment success in patients co-infected with both HIV and HCV.

HCV Viral Load: A Crucial Indicator of Treatment Outcomes

The authors analyzed the data from [research methodology] to assess the association between baseline and week 4 HCV viral load and virological outcomes in patients co-infected with HIV and HCV. Their findings suggest that HCV viral load at these time points can serve as a valuable predictor of treatment success, guiding clinical decision-making.

The Importance of HCV Viral Load Monitoring: Guiding Treatment Strategies

This study underscores the importance of monitoring HCV viral load during treatment, as it can provide crucial information about treatment effectiveness. This information can then guide treatment adjustments and ensure the best possible outcomes for patients.

Dr. Camel's Conclusion

This study highlights the complexities of treating co-infections like HIV and HCV. The careful monitoring of HCV viral load is crucial to guiding treatment strategies and optimizing outcomes for individuals battling these challenging conditions.
Date :
  1. Date Completed 2016-10-05
  2. Date Revised 2017-08-12
Further Info :

Pubmed ID

26528903

DOI: Digital Object Identifier

10.1016/j.jcv.2015.10.010

Related Literature

Article Analysis
・Effects of boceprevir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.